Aldeyra Therapeutics Schedules Webcast and Conference Call for Third Quarter 2015 Financial and Operating Results

November 5, 2015

LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial and operating results for the third quarter ended September 30, 2015 on Thursday, November 12, 2015, prior to the market open.

Aldeyra will hold a conference call on Thursday, November 12, 2015 at 8:30 a.m. ET. Dr. Todd Brady, President and Chief Executive Officer, and Stephen Tulipano, Chief Financial Officer, will host the conference call to discuss Aldeyra's financial and operating results for the third quarter ended September 30, 2015. The dial-in numbers are 1-877-407-0784 for domestic callers and 1-201-689-8560 for international callers. The conference ID number for both is 13623628. A live webcast of the conference call will also be available on the investor relations page of Aldeyra's corporate website at www.aldeyra.com.

After the live webcast, the event will remain archived on Aldeyra's website for one year. In addition, a telephonic replay of the call will be available until November 19, 2015. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 13623628.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap aldehydes. Aldeyra has initiated clinical testing of NS2 for the treatment of Sjögren-Larsson Syndrome, noninfectious anterior uveitis, and allergic conjunctivitis. NS2 has not been approved for sale in the U.S. or elsewhere. www.aldeyra.com

CONTACT: Corporate Contact:

         Stephen Tulipano

         Aldeyra Therapeutics, Inc.

         Tel: +1 781-761-4904 Ext. 205

         stulipano@aldeyra.com

         

         Investor Contact:

         David Burke

         The Ruth Group

         Tel: +1 646-536-7009

         dburke@theruthgroup.com

Safe Harbor Disclosure

This video content contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Aldeyra’s possible or assumed future results of operations, expenses and financing needs, business strategies and plans, research and development plans or expectations, trends, the structure, timing and success of Aldeyra’s planned or pending clinical trials, expected milestones, market sizing, pricing and reimbursement, competitive position, regulatory matters, industry environment and potential growth opportunities, among other things. Actual results or trends could differ materially from those contemplated by these forward-looking statements. For more information, please refer to the risk factors discussed in Aldeyra's periodic filings with the SEC, including the most recent Form 10-Q or 10-K. Any forward-looking statements that are made in the video content are based on assumptions as of the original date of the creation of such video, and Aldeyra undertakes no obligation to update these statements as a result of new information or future events.

Continue to video